Opinion|Videos|September 24, 2025
Future Treatment of Patients With Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how the introduction of Janus kinase (JAK) inhibitor therapies will likely change treatment algorithms for alopecia areata (AA), with insights on how payers should plan for coverage in the coming years and explore the biggest unmet needs for patients with AA and potential improvements in care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- McMichael: How do you see treatment algorithms changing with the introduction of JAK inhibitor therapies?
- How do you think payers should anticipate covering AA in the next few years?
- Friedland: What do you see as the biggest unmet needs for patients with AA and how can these be improved in the future?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
5